Normalised repeat serum prostate-specific antigen: associations with age and magnetic resonance imaging results
DOI:
https://doi.org/10.2340/sju.v59.26662Keywords:
Prostate cancer, diagnosis, prostate-specific antigen, repeat testing, magnetic resonance imaging, ageAbstract
Objective: To assess the value of a repeat prostate-specific antigen measurement (PSA2) before magnetic resonance imaging (MRI) in men with a raised PSA (PSA1) <10 µg/L.
Method: Medical records of men aged < 75 years referred in 2021 for PSA1 3.0–9.9 µg/L (< 70 years) or 5.0–9.9 µg/L (70–74 years) were reviewed. PSA2 was sampled before MRI within 60 days from PSA1. Odds ratios (ORs) were calculated with logistic regression. Chi-square and trend-test were used for categorical variables.
Results: A total of 341 men were included. Median time between PSA1 and PSA2 was 28 days (interquartile range 20–35 days). PSA normalised in 16% (95% confidence interval [CI]: 13–21). Younger men were more likely to have a normal PSA2 (OR: 0.95 per year older, 95% CI: 0.92–0.99). Among men aged < 70 years, those with PSA1 < 5 µg/L were more likely to have normalised PSA2 than those with PSA1 ≥ 5 µg/L (21% vs. 10%, p = 0.01). A greater proportion of men with normalised PSA2 had a Prostate Imaging Data and Reporting System MRI score of 1–3 than men with non-normalised PSA2 (93% vs. 77%, p = 0.01).
Conclusions: A clinically significant proportion of men with a moderately raised PSA value have a normal PSA2. Younger men and men with lower PSA1 were more likely to have a normal PSA2. Few men with normalised PSA2 had suspicious MRI findings. Routine repeat PSA-testing may be motivated in men with a moderately raised PSA value to save MRI resources, particularly in younger men.
Downloads
References
Rosario DJ, Lane JA, Metcalfe C, et al. Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study. Eur Urol. 2008;53(4):777–84.
https://doi.org/10.1016/j.eururo.2007.11.064 DOI: https://doi.org/10.1016/j.eururo.2007.11.064
De Nunzio C, Lombardo R, Nacchia A, et al. Repeat prostatespecific antigen (PSA) test before prostate biopsy: a 20% decrease in PSA values is associated with a reduced risk of cancer and particularly of high-grade cancer. BJU Int. 2018;122(1):83–8.
https://doi.org/10.1111/bju.14197 DOI: https://doi.org/10.1111/bju.14197
Nordström T, Adolfsson J, Grönberg H, et al. Repeat prostate-specific antigen tests before prostate biopsy decisions. J Natl Cancer Inst. 2016;108(12):djw165.
https://doi.org/10.1093/jnci/djw165 DOI: https://doi.org/10.1093/jnci/djw165
Lavallée LT, Binette A, Witiuk K, et al. Reducing the harm of prostate cancer screening: repeated prostate-specific antigen testing. Mayo Clin Proc. 2016;91(1):17–22.
https://doi.org/10.1016/j.mayocp.2015.07.030 DOI: https://doi.org/10.1016/j.mayocp.2015.07.030
Xie J, Jin C, Liu M, et al. MRI/transrectal ultrasound fusion-guided targeted biopsy and transrectal ultrasound-guided systematic biopsy for diagnosis of prostate cancer: a systematic review and meta-analysis. Front Oncol. 2022;12:880336.
https://doi.org/10.3389/fonc.2022.880336 DOI: https://doi.org/10.3389/fonc.2022.880336
Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56(4):265–73.
https://doi.org/10.1080/21681805.2022.2094462 DOI: https://doi.org/10.1080/21681805.2022.2094462
Connolly D, Black A, Murray LJ, et al. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA? Prostate Cancer Prostatic Dis. 2009;12(1):47–51.
https://doi.org/10.1038/pcan.2008.37 DOI: https://doi.org/10.1038/pcan.2008.37
Arsov C, Albers P, Herkommer K, et al. A randomized trial of risk-adapted screening for prostate cancer in young men – results of the first screening round of the PROBASE trial. Int J Cancer. 2022;150(11):1861–9. DOI: https://doi.org/10.1002/ijc.33940
https://doi
Kobayashi M, Kijima T, Yashi M, et al. Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels. Prostate Int. 2023;11(1):27–33.
https://doi.org/10.1016/j.prnil.2022.08.001 DOI: https://doi.org/10.1016/j.prnil.2022.08.001
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Hang Dang, Victoria Huang, Ola Bratt
This work is licensed under a Creative Commons Attribution 4.0 International License.
Acta Chirurgica Scandinavica Society owns the copyright for all material published until Volume 57 (2023) unless otherwise specified. As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
